{"name": "Taligen Therapeutics",
 "permalink": "taligen-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/taligen-therapeutics",
 "homepage_url": "http://www.taligentherapeutics.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2004,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@taligentherapeutics.com",
 "phone_number": "617-444-8443",
 "description": "Treatment of Inflammatory diseases",
 "created_at": "Mon Jun 22 07:35:03 UTC 2009",
 "updated_at": "Sun Mar 31 11:18:02 UTC 2013",
 "overview": "\u003Cp\u003ETaligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company\u0026#8217;s lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen\u0026#8217;s founders have validated as an important amplification loop in the inflammation process.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       61],
      "assets/images/resized/0005/0041/50041v2-max-150x150.jpg"],
     [[250,
       102],
      "assets/images/resized/0005/0041/50041v2-max-250x250.jpg"],
     [[350,
       144],
      "assets/images/resized/0005/0041/50041v2-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": " President and co-founder",
    "person":
     {"first_name": "Woodruff",
      "last_name": "Emlen",
      "permalink": "woodruff-emlen",
      "image": null}},
   {"is_past": true,
    "title": "CEO",
    "person":
     {"first_name": "Abbie",
      "last_name": "Celniker",
      "permalink": "abbie-celniker",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7349/267349v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7349/267349v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7349/267349v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$78.8M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.taligentherapeutics.com/press/080201Taligen_Series%20B.pdf",
    "source_description": "Taligen Therapeutics Secures Series B Financing",
    "raised_amount": 65000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 1,
    "funded_day": 1,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Alta Partners",
         "permalink": "alta-partners",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0003/4978/34978v1-max-150x150.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-250x250.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Clarus Ventures",
         "permalink": "clarus-ventures",
         "image":
          {"available_sizes":
            [[[150,
               82],
              "assets/images/resized/0005/0042/50042v2-max-150x150.png"],
             [[250,
               137],
              "assets/images/resized/0005/0042/50042v2-max-250x250.png"],
             [[308,
               169],
              "assets/images/resized/0005/0042/50042v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "High Country Venture",
         "permalink": "high-country-venture",
         "image":
          {"available_sizes":
            [[[150,
               75],
              "assets/images/resized/0002/8103/28103v3-max-150x150.jpg"],
             [[228,
               114],
              "assets/images/resized/0002/8103/28103v3-max-250x250.jpg"],
             [[228,
               114],
              "assets/images/resized/0002/8103/28103v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020100823e68n00003\u0026r=Rss\u0026s=DJFVW",
    "source_description": " Taligen Set To Enter Clinic After Securing $10M Series B Tranche",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 8,
    "funded_day": 23,
    "investments":
     []},
   {"round_code": "a",
    "source_url": "http://www.taligentherapeutics.com/news/pdfs/2006_0801_Taligen_SeriesA.pdf",
    "source_description": "Taligen Therapeutics Announces Successful Achievement of Series A Milestone",
    "raised_amount": 3750000.0,
    "raised_currency_code": "USD",
    "funded_year": 2005,
    "funded_month": 8,
    "funded_day": 1,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Tango",
         "permalink": "tango",
         "image":
          {"available_sizes":
            [[[145,
               89],
              "assets/images/resized/0025/5074/255074v1-max-150x150.png"],
             [[145,
               89],
              "assets/images/resized/0025/5074/255074v1-max-250x250.png"],
             [[145,
               89],
              "assets/images/resized/0025/5074/255074v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "High Country Venture",
         "permalink": "high-country-venture",
         "image":
          {"available_sizes":
            [[[150,
               75],
              "assets/images/resized/0002/8103/28103v3-max-150x150.jpg"],
             [[228,
               114],
              "assets/images/resized/0002/8103/28103v3-max-250x250.jpg"],
             [[228,
               114],
              "assets/images/resized/0002/8103/28103v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "University License Equity Holdings",
         "permalink": "university-license-equity-holdings",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 111000000.0,
   "price_currency_code": "USD",
   "term_code": "cash",
   "source_url": "http://www.masshightech.com/stories/2011/01/31/daily2-Taligen-Therapeutics-acquired-for-111M.html",
   "source_description": "Taligen Therapeutics acquired for $111M",
   "acquired_year": 2011,
   "acquired_month": 1,
   "acquired_day": 31,
   "acquiring_company":
    {"name": "Alexion Pharmaceuticals",
     "permalink": "alexion-pharmaceuticals",
     "image":
      {"available_sizes":
        [[[150,
           33],
          "assets/images/resized/0011/9814/119814v1-max-150x150.png"],
         [[216,
           48],
          "assets/images/resized/0011/9814/119814v1-max-250x250.png"],
         [[216,
           48],
          "assets/images/resized/0011/9814/119814v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "Headquarters",
    "address1": "245 First Street",
    "address2": "Suite 1830, 18th Floor",
    "zip_code": "02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": 42.3634664,
    "longitude": -71.0786638}],
 "milestones":
  [{"description": "has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 31,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily2-Taligen-Therapeutics-acquired-for-111M.html",
    "source_text": null,
    "source_description": "Taligen Therapeutics acquired for $111M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Taligen Therapeutics",
      "permalink": "taligen-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        79],
       "assets/images/resized/0005/0049/50049v1-max-150x150.jpg"],
      [[250,
        133],
       "assets/images/resized/0005/0049/50049v1-max-250x250.jpg"],
      [[450,
        239],
       "assets/images/resized/0005/0049/50049v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}